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Introduction
Prevalence of obesity is increasing rapidly both in 
developed and developing countries, already reach-
ing epidemic levels [1]. Currently, bariatric proce-
dures are considered to be the sole proven method 
for permanent body weight reduction in the majority 
of treated patients, and achieve the highest remis-
sion rate for comorbidities [2].
Previously, the restriction effect resulting in re-
duction of possible food intake and limited food 
absorption were considered to be the main mech-
anisms underlying the decrease in body weight 
following bariatric procedures. So far, over twenty 
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A b s t r a c t
Introduction: The hormonal brain-gut axis is a crucial element in appetite control and the response to surgical treat-
ment for super obesity. However, mechanisms underlying the metabolic response to surgical treatment for morbid 
obesity are still not clearly specified.
Aim: To evaluate and compare the effects of surgical treatment for super obesity by laparoscopic sleeve gastrectomy 
(LSG) and by laparoscopic Roux-en-Y gastric bypass (LRYGB) on selected incretins and appetite-controlling hormones.
Material and methods: Thirty-five patients were enrolled in a prospective study. Laparoscopic sleeve gastrectomy 
was performed in 45.8% of patients, and LRYGB in the remaining 54.2% of patients. Before the procedure fasting 
blood serum was collected from patients and preserved, to determine levels of selected incretins and brain-gut hor-
mones: glucagon-like peptide 1 (GLP-1), peptide YY (PYY), leptin, and ghrelin.
Results: Twenty-eight patients came to a follow-up visit 12 months after the surgery. In these patients selected pa-
rameters were determined again. The percentage weight loss was 58.8%. The ghrelin levels had decreased, and no 
statistically significant difference was observed between the two procedures. After both surgical procedures a statis-
tically significant reduction in the leptin level was also observed. Peptide YY levels statistically significantly increased 
in the whole studied group. The GLP-1 level increased after the surgical procedure. However, the observed change 
was not statistically significant.
Conclusions: Both treatment methods result in modification of secretion patterns for selected gastrointestinal hor-
mones, and this was considered to be a beneficial effect of bariatric treatment. The laparoscopic sleeve gastrectomy, 
being a procedure resulting in a metabolic response, seems to be an equally effective method for treatment of super 
obesity and comorbidities as the laparoscopic gastric bypass.
Key words: bariatric surgery, laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), ghrelin, leptin, 
glucagon-like peptide 1.
Changes in levels of selected incretins and appetite-controlling hormones following surgical treatment for morbid obesity
459Videosurgery and Other Miniinvasive Techniques 3, September/2015
hormonally active substances have been identified, 
secreted by gastrointestinal structures and partici-
pating in mechanisms controlling hunger and sa-
tiation. Changes in their secretion are considered 
to be responsible for metabolic effects of bariatric 
procedures [3]. Therefore, the hormonal brain-gut 
axis is a crucial component in appetite control and 
a  response to surgical treatment for super obesity 
[4]. Adaptive changes in secretion of those crucial 
substances lead to body weight reduction and ben-
eficial metabolic effects [5]. Although there are nu-
merous publications available studying the effect of 
bariatric procedures on changes in hormonal axes 
controlling appetite, the mechanisms underlying 
a metabolic response to surgical treatment for super 
obesity are not yet fully known and clearly defined. 
Studies comparing the effect of individual surgical 
procedures on changes in selected hormones and 
incretins in the gastrointestinal tract are also lack-
ing, and they would support better qualification of 
patients for an appropriate treatment method [6].
Aim 
The aim of this study is to evaluate and compare 
the effects of surgical treatment for morbid obesity 
by laparoscopic sleeve gastrectomy (LSG) and by lap-
aroscopic gastric bypass on selected incretins and 
appetite-controlling hormones.
Material and methods
A prospective study was conducted in a group of 
patients with super obesity undergoing operations 
at the 2nd Chair of Surgery, Jagiellonian University 
Medical College (JUMC).
Criteria for enrolment in the study group:
•	 patients with super obesity meeting qualification 
criteria for bariatric surgery developed by the Met-
abolic and Bariatric Surgery Section of the Polish 
Surgical Society, i.e.:
– body mass index (BMI) exceeding 40 kg/m2,
–  BMI exceeding 35 kg/m2 when obesity-related 
diseases are diagnosed, including type 2 dia-
betes, hypertension, lipid disorders, obstructive 
sleep apnoea,
– age 18–65 years;
•	 patients subjected to the LSG or the laparoscopic 
Roux-en-Y gastric bypass;
•	 postoperative period without complications;
•	 written consent to participate in the study.
Patients who: underwent revision surgery, suf-
fered delayed surgical complications, did not report 
to a follow-up visit 12 months after the surgery, were 
diagnosed with mental illness, were diagnosed with 
alcohol or drug dependence were excluded from the 
study group.
Before the procedure, body weight and BMI 
were determined in all patients included in the 
study, using the TANITA BC-420S MA apparatus. 
Furthermore, information of super obesity com-
plications (hypertension and type 2 diabetes) 
was collected. On the day of the procedure, in the 
morning, fasting blood serum was collected from 
patients and preserved, to determine levels of 
selected incretins and brain-gut axis hormones: 
glucagon-like peptide-1 (GLP-1), peptide YY (PYY), 
leptin, and ghrelin. 
In the period from April 2013 to January 2014, 
35 people meeting the inclusion criteria and who 
gave their informed consent for participation in 
the study were enrolled in the study, selected from 
51 patients treated for super obesity at the 2nd 
Chair of Surgery, JUMC. The patients were quali-
fied for specific surgical procedures. Then, the 
group of volunteers were covered by a prospective 
analysis. Fourteen (40%) men and 21 (60%) wom-
en gave their consent to participate in the study. 
The mean age of patients enrolled in the study 
was 42.75 years (44.4 for women, 41.1 for men). 
In the studied group the mean body weight before 
the surgery was 146.2 kg and the mean BMI index 
was 50.44 kg/m2. Before the surgery, 15 (42.8%) 
patients were diagnosed with hypertension, and 
6 (17.2%) patients were diagnosed with type 2 
diabetes. Laparoscopic sleeve gastrectomy was 
performed in 16 (45.8%) patients, and laparoscop-
ic gastric bypass was performed in the remaining 
19 (54.2%) patients. Of the studied patients, 7 did 
not come to a follow-up visit 12 months after the 
surgical treatment (4 LSG and 3 Roux-en-Y gastric 
bypass (LRYGB) patients). The final analysed group 
consisted of 28 patients (Figure 1).
The selected parameters were reassessed during 
the follow-up visit. Also material for determination 
of selected biochemical parameters was collected. 
When the whole material was collected, it was de-
livered to the Diagnostic Laboratory at the Chair of 
Clinical Biochemistry, JUMC, where specific parame-
ters were determined. Characteristics of the studied 
group are shown in Table I.
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Description of laboratory procedures applied
Leptin, ghrelin, GLP-1 and PYY levels were deter-
mined with commercially available reagent kits from 
Millipore, St. Charles, U.S. Leptin serum levels were 
determined with the immunoenzymatic technique 
ELISA using the Human Leptin ELISA Kit. The meth-
od was characterised by sensitivity of 0.78 ng/ml, 
and inter- and intra-assay coefficients of variability 
below 4.6% and 6.2%, respectively.
Ghrelin levels were determined with the immu-
noenzymatic technique using the Human Ghrelin 
(Total) ELISA Kit. The method determined two 
ghrelin forms: active and des-octanoyl. The method 
sensitivity limit corresponded to 0.50 pg/ml, and in-
ter- and intra-assay coefficients of variability were 
below 1.91% and 7.81%, respectively. The serum 
levels of active GLP-1 were determined with the im-
munoenzymatic technique based on fluorescence 
detection, using fluorogenic substrate for alkaline 
phosphatase, 4-methylumbelliferyl phosphate. The 
Glucagon-Like Peptide-1 (Active) ELISA Kit used was 
characterised by sensitivity of 2 pM and inter- and 
intra-assay coefficients of variability below 9% and 
13%, respectively. Peptide YY levels were determined 
with the immunoenzymatic technique using the Hu-
man PYY (Total) ELISA Kit. The analytical sensitivity 
of this method was 16.07 pg/ml, while inter- and 
intra-assay coefficients of variability did not exceed 
5.78% and 16.50%, respectively.
Statistical analysis
The statistical analysis was conducted with the 
Statistica 10 PL package. The two groups (according 
to the procedure type) were compared with the Stu-
dent t-test and, when assumptions for standard dis-
tribution were not met, with the Mann-Whitney test. 
To compare changes in time, an analysis of variance 
Figure 1. Study plan (flow chart)
Table I. Detailed characteristics of the studied group
Parameter Gender Sleeve gastrectomy (LSG) Gastric bypass (LRYGB) Total
Gender Female 8 9 17
28
Male 4 7 11
Age [years] Female 43.22 45.87 44.4 
42.75 
Male 40.7 42.9 41.1 
Weight [kg] Female 134.8 141.1 137.95 
146.2 
Male 157.75 160.5 159.12 
BMI [kg/m2] Female 50.66 51.5 51.03 
50.44 
Male 48.74 49.76 49.29 
Hypertension Female 2 7 9
15
Male 2 4 6
Type 2 diabetes Female 0 1 1
6
Male 2 3 5
Patients treated for morbid obesity at 2nd 
Department of Surgery JUMC (n = 51)
Excluded from the study (n = 16)
Surgical treatment (n = 35)
LSG (n = 16) LRYGB (n = 19)
Analysed (n = 28)
Analysed patients (n = 12) Analysed patients (n = 16)
Follow-up (12 months)
Patients didn’t reported  
for follow-up (n = 4)
Patients didn’t reported  
for follow-up (n = 3)
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with repeated measurements was used, and when 
the criteria were not met, relevant nonparametric 
tests (Friedman test, Wilcoxon signed-rank test) were 
used. In all analyses, effects for which the probability 
value, p, was below the adapted level of significance 
a = 0.05 (p < 0.05) were considered significant.
Bioethics committee
The study was approved by the Bioethics Com-
mittee, Jagiellonian University. After getting thor-
oughly acquainted with assumptions and objectives 
of the study, all patients enrolled in the study group 
gave their written informed consent to participate 
in the study. 
Results
The mean body weight measured during the fol-
low-up visit 12 months after the surgery was 97.1 kg. 
The mean weight was 92.8 kg in the group of patients 
after LSG and 101.9 kg in the group after laparoscopic 
gastric bypass (p = 0.52). The mean BMI after the sur-
gical procedure was 33.4 kg/m2, and 32.5 kg/m2 and 
34.4 kg/m2 in the group after LSG and laparoscopic 
gastric bypass, respectively (p = 0.32). The average 
percentage weight loss (%EWL) was 58.8%, and the 
average percentage excess BMI loss (%EBMIL) was 
68.85%. One year after the surgical procedure no sig-
nificant differences were noted between the proce-
dures in terms of body mass reduction rate (Table II).
From 15 patients diagnosed with hypertension 
before the surgical procedure, in 11 (73%) no clini-
cal signs of hypertensions were observed during the 
follow-up visit 12 months after the procedure, and 
in the remaining patients the doses of hypotensive 
medicines were reduced. Significant improvement 
was also observed for type 2 diabetes, versus the 
period before the surgery. Only in 1 of 6 patients 
diagnosed with type 2 diabetes before the bariat-
ric procedure were the symptoms of sugar manage-
ment disorder maintained during the follow-up visit. 
This means that in 5 (83.3%) of the patients diabe-
tes resolved with applied treatment.
When analysing results for activity levels of 
selected incretins and gastrointestinal tract hor-
mones, statistically significant differences were ob-
served for ghrelin, leptin and PYY levels. Observed 
changes in GLP-1 levels were not statistically signif-
icant (Figure 2).
In the whole studied group, the ghrelin lev-
el dropped from the mean level of 350.2 pg/ml to 
100.34 pg/ml (p = 0.003). The ghrelin level decreased 
from 384.6 pg/ml to 105.5 pg/ml (0.024) in patients 
treated with the laparoscopic sleeve gastrectomy, 
and from 337.3 pg/ml to 98.36 pg/ml (0.025) in pa-
tients treated with the laparoscopic gastric bypass. 
No statistically significant difference was observed 
between those two procedures (Figure 3).
A  significant drop was also observed for leptin 
levels (18.4 ng/ml) vs. its levels before the surgery 
(55.7 ng/ml). The obtained result is statistically sig-
nificant (p = 0.005). The results were similar for both 
types of procedure, and no differences were demon-
strated between them. The leptin level decreased 
from 48.6 ng/ml to 9.78 ng/ml (p = 0.023) for the 
laparoscopic sleeve gastrectomy, and from 58.4 ng/
ml to 21.6 ng/ml (p = 0.035) in patients treated with 
the laparoscopic gastric bypass (Figure 4).
When analysing results concerning PYY levels, 
a  statistically significant increase was observed 
in the whole studied group, from 116.6  pg/ml to 
182.9  pg/ml (p = 0.01). Also for PYY the changes 
observed after both surgical procedures were sta-
tistically significant. The PYY level increased from 
Table II. Body mass reduction rate depending on 
type of surgical procedure
LSG LRYGB Value of p
%EWL 61.2% 56.19% 0.1
%EBMIL 71.8% 65.5% 0.09
Figure 2. Changes in activity levels of selected 
incretins and gastrointestinal tract hormones 
following surgical treatment for super obesity
 Ghrelin  Leptin PYY GLP-1
 [pg/ml] [ng/ml] [pg/ml] [pmol/l]
 Before          After
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0
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Figure 3. Change in ghrelin levels following 
a given type of surgical procedure
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Figure 4. Change in leptin levels following a giv-
en type of surgical procedure
 Before treatment After treatment
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Figure 6. Change in GLP-1 levels following a giv-
en type of surgical procedure
 Before treatment After treatment
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Figure 5. Change in PYY levels following a given 
type of surgical procedure
 Before treatment After treatment
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117.6 pg/ml to 193.8 pg/ml (p = 0.031) for the lap-
aroscopic sleeve gastrectomy, and from 116.19 pg/
ml to 178.8 pg/ml (p = 0.037) for the laparoscopic 
gastric bypass (Figure 5).
After the surgical treatment, the mean GLP-1 lev-
el increased from 5.6 pmol/l to 6.49 pmol/l. Howev-
er, the observed change was not statistically signifi-
cant, both in the whole studied group (p = 0.42) and 
for individual types of surgical procedure (LSG p = 
0.4 and LRYGB p = 0.46) (Figure 6). Detailed values 
of the studied parameters are provided in Table III.
Discussion
In medical circles, interest in surgical treatment 
of obesity is huge, and this is reflected in the num-
ber of conducted studies and resultant publications. 
Bariatric surgery ceased to be just a  method for 
treatment of obesity. Increasingly often it is empha-
sised that its main aim is treatment of comorbidities 
through its influence on patient’s metabolism. Thus 
it was given another name “metabolic surgery”. 
Although metabolic effects of bariatric proce-
dures seem to be relatively well known, still many 
aspects remain unclear or doubtful, or even opin-
ions on them found in the literature are contradic-
tory. One of the bariatric procedures with well-docu-
mented and explained effects is the gastric bypass, 
currently the most commonly performed bariatric 
procedure in the world. Its influence on metabolism 
of operated patients through hormonal changes oc-
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curring directly after the surgery is a subject of nu-
merous publications and reports. 
However, current tendencies show a  constant 
increase in interest in the LSG, and in the number 
of procedures conducted with this technique. It is 
know that sleeve gastrectomy is an effective and 
relatively safe procedure [7]. The achieved body 
mass reduction, previously considered to be sole-
ly the effect of the restrictive mechanism reducing 
possibilities for food supply, is currently questioned. 
The opinion that LSG also results in a metabolic re-
sponse appears with increasing frequency. While 
the influence of this treatment method on postop-
erative reduction in the ghrelin level and a  resul-
tant decrease of appetite seems obvious, because 
the main source of ghrelin is cells in the fundus re-
moved during the procedure, its influence on the 
other components controlling the brain-gut axis 
remains unclear [8].
The present study was designed to evaluate the 
metabolic effect of the two bariatric procedures cur-
rently most frequently performed in the world, that 
is, the LSG and the laparoscopic gastric bypass. The 
answer to this question may be a valuable guideline 
when qualifying patients with super obesity for spe-
cific surgical procedures.
The results of activity analyses of selected incre-
tins and gastrointestinal tract hormones showed sta-
tistically significant differences for ghrelin, leptin and 
PYY levels. What is interesting, the observed changes 
in GLP-1 levels were not statistically significant. 
The observed reduction in the ghrelin levels in 
patients after LSG is not surprising, and that effect 
was expected even before the study was conducted. 
This effect results from the fact that the number of 
cells producing this hormone is reduced with remov-
al of a  fragment of the resected stomach including 
its fundus [9, 10]. It was surprising, however, that in 
this study a significant reduction in the ghrelin level 
was also noted for the laparoscopic gastric bypass, 
comparable to the laparoscopic sleeve gastrectomy. 
In the gastric bypass procedure the main fraction of 
cells producing ghrelin is in the inactive, bypassed 
part of the stomach, and this possibly contributes 
to the reduction in its blood levels. An additional im-
plied mechanism underlying a  decrease in ghrelin 
secretion after gastric bypass surgery is a lack of me-
chanical stretching of the fundus by food, as it does 
not enter this part of the gastrointestinal tract after 
the surgery. Similar conclusions can be drawn when 
analysing results of Nanniperii’s study, in which a sig-
nificant reduction in ghrelin levels was also observed 
for both types of surgical procedure [11].
A  reduction in body mass is accompanied by 
a  reduction in fatty tissue in the body. Therefore, 
the number of adipocytes constituting a source of 
leptin decreases, and this leads to a  reduction in 
blood levels of this peptide. In the conducted study, 
a  significant reduction in the leptin level was ob-
served for both surgical techniques. However, in the 
authors’ opinion this effect is not directly related to 
changes in the hormonal axes, but rather results di-
rectly from the weight loss. In this study both types 
of surgery led to a  comparable reduction in body 
weight. In both cases similar changes were also ob-
served for the leptin levels. As expected, no signif-
icant differences were noted between the surgery 
procedures. The reduction in the leptin levels after 
Table III. Detailed results of activity determinations for selected incretins and gastrointestinal tract hor-
mones in patients treated for super obesity
Parameter Procedure Before the procedure After the procedure Value of p
Ghrelin [pg/ml] LSG 384.6267 105.5967 0.024
LRYGB 337.3025 98.36875 0.025
Leptin [ng/ml] LSG 48.65833 9.781667 0.023
LRYGB 58.43813 21.63375 0.035
PYY [pg/ml] LSG 117.6967 193.815 0.031
LRYGB 116.1913 178.8975 0.037
GLP-1 [pmol/ml] LSG 5.057 5.325 0.4
LRYGB 7.030 5.706 0.46
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bariatric treatment was also observed by Buchwald 
[12]. Similarly, Terra, in her work on delayed effects 
of the LSG and the laparoscopic gastric bypass, ob-
served a significant drop in the leptin levels for both 
procedures [13].
When analysing literature data at the stage of 
planning of this study, an increase in PYY and GLP-1 
levels was expected following the LRYGB procedure. 
The authors were surprised to see the increase in 
levels of incretins secreted by L cells in jejunum af-
ter both surgical procedures. For PYY, the increase in 
its levels appeared to be significant (p = 0.01) one 
year after bariatric treatment. Therefore, both the 
LSG and the laparoscopic gastric bypass resulted in 
a similar increase in peptide YY levels. For LSG this ef-
fect is possibly related to the post-treatment change 
in the gastric emptying mechanism, so gastric con-
tent is moved to the duodenum much faster, thus 
stimulating the L cells. Although the mean GLP-1 lev-
el after both surgical procedures changed slightly in 
both groups, no statistical significance was noted for 
observed changes. In her study Rosa Morinigo doc-
umented a  change in the GLP-1 activity level both 
6 weeks after the gastric bypass surgery and during 
a  follow-up visit 12 months after discharge from 
the hospital [14]. Therefore, there are reports avail-
able in the literature confirming the increase in the 
GLP-1 level after gastric bypass surgery. Its increase 
and influence on the increased post-meal insulin se-
cretion from pancreatic beta cells is the main sug-
gested mechanism underlying resolution of type 2 
diabetes after this surgical procedure. Some studies 
also aimed at comparing individual types of surgical 
procedures in terms of their possible effect on lev-
els of selected gastrointestinal hormones, including 
PYY and GLP-1. For example, in his paper Rainehr 
described a  significant increase in PYY and GLP-1 
when comparing the effects of the gastric bypass 
and gastric banding surgery. The observed change 
was significantly higher after the gastric bypass [15]. 
However, studies comparing the gastric bypass with 
the LSG remain scarce. One such study is the paper 
of Yousseif, who demonstrated a significant increase 
in PYY and GLP-1 levels after both of these surgical 
procedures. However, in patients after the LSG the 
levels of studied proteins were slightly lower during 
a follow-up [16]. It seems that the lack of statistical-
ly significant increase in GLP-1 levels after surgical 
treatment observed in this study may result from 
a  low number of patients enrolled in the study. No 
significant results were observed in both groups of 
patients, operated with the gastric bypass technique 
and with the LSG technique. Therefore, it seems im-
possible to draw conclusions on possible differences 
between the procedures.
Conclusions
The present study and data available in the lit-
erature unambiguously indicate that surgical treat-
ment for super obesity, either with the laparoscopic 
gastric bypass or with the LSG, leads to effective 
body mass reduction. After those two procedures an 
improvement in diseases caused by obesity (hyper-
tension and type 2 diabetes) is observed. Both treat-
ment methods result in modification of secretion 
patterns for selected gastrointestinal hormones, 
and this was considered to be a beneficial effect of 
bariatric treatment. The laparoscopic sleeve gastrec-
tomy, being a procedure resulting in a metabolic re-
sponse, seems to be an equally effective method for 
treatment of super obesity and comorbidities as the 
laparoscopic gastric bypass.
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